These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 39397502)

  • 1. Hospitalization Outcomes of Patients with Type 2 Diabetes Mellitus Complicated with Diabetic Ketoacidosis.
    Keler M; Vlasov P; Elkan M; Koren S; Koren R
    Isr Med Assoc J; 2024 Oct; 26(9):566-571. PubMed ID: 39397502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in Hospital Admission for Diabetic Ketoacidosis in Adults With Type 1 and Type 2 Diabetes in England, 1998-2013: A Retrospective Cohort Study.
    Zhong VW; Juhaeri J; Mayer-Davis EJ
    Diabetes Care; 2018 Sep; 41(9):1870-1877. PubMed ID: 29386248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
    Kim YG; Jeon JY; Han SJ; Kim DJ; Lee KW; Kim HJ
    Diabetes Obes Metab; 2018 Aug; 20(8):1852-1858. PubMed ID: 29569427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of clinical characteristics and treatment outcomes between initially diagnosed type 1 and type 2 diabetes mellitus patients presenting with diabetic ketoacidosis.
    Mookpaksacharoen O; Choksakunwong S; Lertwattanarak R
    BMC Endocr Disord; 2024 Jul; 24(1):114. PubMed ID: 39010018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and biochemical determinants of length of stay, readmission and recurrence in patients admitted with diabetic ketoacidosis.
    Ata F; Khan AA; Khamees I; Iqbal P; Yousaf Z; Mohammed BZM; Aboshdid R; Marzouk SKK; Barjas H; Khalid M; El Madhoun I; Bashir M; Kartha A
    Ann Med; 2023 Dec; 55(1):533-542. PubMed ID: 36745515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Admissions for diabetic ketoacidosis in ethnic minority groups in a city hospital.
    Nyenwe E; Loganathan R; Blum S; Ezuteh D; Erani D; Palace M; Ogugua C
    Metabolism; 2007 Feb; 56(2):172-8. PubMed ID: 17224329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics and outcomes of care in patients hospitalized with diabetic ketoacidosis.
    Eledrisi MS; Alkabbani H; Aboawon M; Ali A; Alabdulrazzak I; Elhaj M; Ahmed A; Alqahwachi H; Daghfal J; Beshyah SA; Malik RA
    Diabetes Res Clin Pract; 2022 Oct; 192():110041. PubMed ID: 35985426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rate and Predictors of 30-day Readmission Following Diabetic Ketoacidosis in Type 1 Diabetes Mellitus: A US Analysis.
    Shaka H; Aguilera M; Aucar M; El-Amir Z; Wani F; Muojieje CC; Kichloo A
    J Clin Endocrinol Metab; 2021 Aug; 106(9):2592-2599. PubMed ID: 34043791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis.
    Liu H; Sridhar VS; Perkins BA; Rosenstock J; Cherney DZI
    Curr Diab Rep; 2022 Jul; 22(7):317-332. PubMed ID: 35633439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On-label use of sodium-glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis in patients with type 1 diabetes.
    Horii T; Oikawa Y; Atsuda K; Shimada A
    J Diabetes Investig; 2021 Sep; 12(9):1586-1593. PubMed ID: 33448127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing patient characteristics and outcomes in type 1 versus type 2 diabetes with diabetic ketoacidosis: a review and a propensity-matched nationwide analysis.
    Shaka H; Wani F; El-Amir Z; Dahiya DS; Singh J; Edigin E; Eseaton P; Kichloo A
    J Investig Med; 2021 Aug; 69(6):1196-1200. PubMed ID: 33972382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics of diabetic ketoacidosis in users and non-users of SGLT2 inhibitors.
    Jeon JY; Kim SK; Kim KS; Song SO; Yun JS; Kim BY; Kim CH; Park SO; Hong S; Seo DH; Seo JA; Noh JH; Kim DJ;
    Diabetes Metab; 2019 Oct; 45(5):453-457. PubMed ID: 30639566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The management of diabetic ketoacidosis at a rural regional hospital in KwaZulu-Natal.
    Ndebele NFM; Naidoo M
    Afr J Prim Health Care Fam Med; 2018 Mar; 10(1):e1-e6. PubMed ID: 29781681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis.
    Hampp C; Swain RS; Horgan C; Dee E; Qiang Y; Dutcher SK; Petrone A; Chen Tilney R; Maro JC; Panozzo CA
    Diabetes Care; 2020 Jan; 43(1):90-97. PubMed ID: 31601640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Differences in clinical characteristics and outcomes of diabetic ketoacidosis (DKA) in Jewish and Bedouin patients].
    Rabaev E; Sagy I; Zaid EA; Nevzorov R; Harman-Boehm I; Zeller L; Barski L
    Harefuah; 2014; 153(3-4):134-8, 241. PubMed ID: 24791549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-Glucose Cotransporter-2 Inhibitors and Risk of Diabetic Ketoacidosis Among Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Colacci M; Fralick J; Odutayo A; Fralick M
    Can J Diabetes; 2022 Feb; 46(1):10-15.e2. PubMed ID: 34116926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population-based incidence of diabetic ketoacidosis in type 2 diabetes: medical claims data analysis in Japan.
    Takeuchi M; Kawamura T; Sato I; Kawakami K
    Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):123-126. PubMed ID: 28752620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re-examining the widespread policy of stopping sodium-glucose cotransporter-2 inhibitors during acute illness: A perspective based on the updated evidence.
    Khunti K; Aroda VR; Bhatt DL; Bozkurt B; Buse JB; Heerspink HL; Inzucchi SE; Lam CSP; Marx N; McMurray JJV; Solomon SD; Kosiborod MN
    Diabetes Obes Metab; 2022 Nov; 24(11):2071-2080. PubMed ID: 35801339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
    Burke KR; Schumacher CA; Harpe SE
    Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.
    Wang L; Voss EA; Weaver J; Hester L; Yuan Z; DeFalco F; Schuemie MJ; Ryan PB; Sun D; Freedman A; Alba M; Lind J; Meininger G; Berlin JA; Rosenthal N
    Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1620-1628. PubMed ID: 31456304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.